Bepotastine besilate ophthalmic solution 1.5% clears the hurdle for allergic ocular itching

Article

The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.

Key Points

Irvine, CA-The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.

The FDA still is required to approve the application and has set a date of Sept. 12 to take further action on the drug.

Bepotastine besilate is an eye-drop treatment that acts as a non-sedating, highly selective antagonist of the histamine receptor. It has been approved in Japan since 2000 to treat allergic rhinitis and urticaria/pruritus.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jade Coats, OD, FAAO, gives her insight on what makes EyeCon valuable for eye care providers.
Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.
Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz
© 2025 MJH Life Sciences

All rights reserved.